of nine patients with medium-chain acyl-C0A dehydrogenase (MCAD) deficiency, two with Very-long-chain acyl-C0A dehydrogenase (VLCAD) deficiency and two with mild-type multiple acyl-C0A dehydrogenase (MAD-rn) deficiency, were analyzed by gas chromatography-mass spectrornetry. In the plasma of patients with MCAD deficiency we found increases of octanoic acid (8:0), decanoic acid (10:0), 4-decenoic acid (10:1 w6), and 4,7-decadienoic acid (10:2w3), all present almost exclusively in free form. The patients with VLCAD deficiency showed increases of mainly 5-tetradecenoic acid (14: 1(09) and to a minor extent 5-dodecenoic acid (12:lco7), 5,8-tetradecadienoic acid (14:2w6) , and 7,10-hexadecadienoic acid (16:2w6), in both the free and esterified fatty acid fraction. The MAD-m patients showed variable increases of all the unusual fatty acids present in MCADand VLCAD-deficient plasma. The 14:1w9, 14:2w6, and 16:2w6 fatty acids were present mainly in the esterified form. Measurement of these fatty acids in plasma by the relatively simple method presented here provides a sensitive and specific aid in the diagnosis of acyl-C0A dehydrogenase deficiency disorders.
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The analysis of urinary organic acids (1), glycine conjugates (2), and acylcarnitines (3) is indispensable in the diagnosis of disorders of mitochondrial fatty acid oxidation. In addition, the analysis of plasma free fatty acids (FFAs) has proved valuable in the diagnosis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency.2 Plasma concentrations of 8:0, 10:0, and 10: 1w6 fatty acids are increased in this disorder. The latter unusual compound, a metabolite of linoleic acid (18: 2w6), is considered pathognomonic for this disease (4-7). On the basis of these findings we supposed that also in other fatty acid oxidation disorders unusual fatty acids might be present in plasma as a reflection of the metabolic block. Here we describe in detail proceDepartment of Pediatrics, University Hospital, Building 1 (P3-P), P.O.Box 9600, 2300 RC Leiden, The Netherlands. VLCAD, very-long-chain acylCoA dehydrogenase; FAME, fatty acid methyl ester; FFA, free fatty acid; FFAME, FFA methyl ester; TFA, total fatty acid; TFAME, TFA methyl ester; MS, mass spectrometry;
and El, electron impact.
Received April 12, 1995; accepted July 21, 1995. dures for the gas chromatographic (GC) determination of both FFAs and total fatty acids (TFAs) in plasma after a one-step transmethylation reaction based on the methods of Lepage and Roy (8, 9 
Materials and Methods

Patients
Included in this study were nine children, ages 0.6-11.7 years, with MCAD deficiency. All patients presented with hypoketotic hypoglycemia. The initial diagnosis was based on the analysis of organic acids in urine, which showed the characteristic pattern of hypoketonuria, dicarboxylic aciduria, and the presence of hexanoylglycine and suberylglycine. Patient 9 died at age 2.2 years in hypoglycemic coma after 2 days of gastroenteritis; blood and urine were sampled postmortem. In all nine patients, the diagnosis was confirmed enzymatically by assay of octanoyl-CoA dehydrogenase activity in cultured fibroblasts and (or) lymphocytes (10). In patients 1, 3, 5, 6, and 9, mutation analysis was performed, and all five appeared to be homozygous for the common A985G mutation (N. Gregersen, Aarhus, Denmark).
In the other four patients no mutation analysis was performed. Two children with mild-type multiple acyl-CoA dehydrogenase (MAD-rn) deficiency were studied. Diagnosis was based on the findings of (hypoketotic) hypoglycemia with dicarboxylic aciduria and increases of ethylmalonic acid, glutaric acid, 2-hydroxyglutaric acid, butyrylglycine, isobutyrylglycine, isovaleryiglycine, hexanoylglycine, and suberylglycine in urine. In addition, fibroblasts from both patient 1, now age 13 years (11), and patient 2, now age 10 years, showed a decreased rate of oxidation of [9,10-3H] myristic acid (12).
Two children with very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency were studied. Patient 1, now age 4.5 years, presented at age 1.5 years with hypoglycemia and hypoketonuria with dicarboxylic aciduria. Patient 2 died 36 h after birth; blood and urine were sampled postmortem, and a hypoketonuric dicarboxylic aciduria without glycine conjugates was found. In both cases the diagnosis was confirmed by establishing deficient palrnitoyl-CoA and behenoyl-CoA dehydrogenase activity in cultured fibroblasts (10, 13, 14 to plasma were linear to at least 1600 and 800 moI/L, respectively (not shown). Given that the (theoretical) amounts of 9:0 methyl ester and 19:0 methyl ester in the hexane extract are 9.80 and 9.23 g, respectively, an ideal FFA determination should lead to a 9:0/19:0 peak area ratio of 1.06 in the GC analysis (assuming equal detector response to the two internal standard methyl esters). Under the optimized GC conditions described above, we found in 41 FFA analyses a mean 9:0/19:0 ratio of 0.81 (CV 10.3%). This ratio indicates there was still some loss of 9:0 methyl ester. FAMEs with chain lengths of 19 carbon atoms were not discriminated under these con- The indicated peaks were identified as: 1, 8:0; 2, 9:0 (mntemalstandard); 3, 10:0; 4, 10:1w6; 5, 10:2w3; 6, 12:0, 7, 12:1w7; 8, 14:0; 9, 14:1w9; 10, 14:1w5; 11, 15:0; 12, 14:2w6; 13, 16:0 dimethylacetal; 14, 16:0; 15, 16:1w9; 16, 16:1w7; 17, 17:0; 18, 16:2w6; 19, 18:0 dimethylacetal; 20, 18:0; 21, 18:1w9; 22, 18:1w7; 23, 19:0 (intemal standard); 24, 18:2w6; 25, l8:3w3; 26, 20:3w6; 27, 20:4w6; 28, 24:1w9; and 29, 22:6w3 :ooling of the reaction mixture afterwards. Because enzene (400 p1) is the solvent in this method, a 10 #{176}C #{252}gher initial oven temperature was found to be optinal.
Preparation of total FAMEs (TFAMEs) from plasma. L'o 100 p1 of blood plasma in a 10-mL glass tube we idded 3.0 p1 of a 3.0 g/L solution of nonanoic acid in riethanol and 6.0 p1 of a 2.94 g/L solution of nonadectnoic acid in methanol (as internal standards) and 2.0 nL of methanol:benzene (4:1, by vol) (9). Acetyl chloide (200 pL) was added slowly for 1 mm with magnetic tirring, the tube was tightly closed, and derivatization vas performed for 1 h at 100 #{176}C in a heating block.
;ubsequently, we carefully added 5 mL of a 6% potas-;ium carbonate solution in water with stirring while ooling in an ice bath, shook the mixture, and kept the ample at 4 #{176}C for at least 30 mm. Finally, we centriuged the sample and isolated as much as possible of he benzene upper layer; of this amount, 1.1 p1 was ubjected to GC analysis.
GC of TFAMEs.
GC and injection were performed in he same way as above, except that the initial oven emperature was 55 #{176}C. The limit of detection (signal-0-noise ratio of 10) for TFAS was -1 mo1/L.
Linearity and reproducibility.
Calibration curves of mounts of the internal standards 9:0 and 19:0 added o plasma were both linear to at least 2400 imoI/L (not hown).
In 43 TFA analyses we found a mean 9:0/19:0 ratio of 1.48, with a CV of 12.3%. This ratio approaches the heoretical ratio of 0.53. A possible explanation for this )etter ratio in comparison with the FFA determination s the slightly lower volatility of benzene than of texane and the larger solvent volume.
Mass spectrometry (MS). MS was performed on a VG
['rio-2 GC-MS system equipped with an HP5890A GC Fisons, Weesp, The Netherlands) and an Intel peronal computer with Masslynx software. The GC conlitions and column were as described above. Helium vas used as the carrier gas at a flow rate of 2.0 mL/min. rhe interface temperature was 250 #{176}C, and the ion ource temperature was 175 #{176}C. El mass spectra were ontinuously recorded from m/z 60 to 375 at a rate of ).95 s per full scan; the ionization energy was 60 eV Lnd the resolution, MJM (10% valley), was --500. Quantification of fatty acids. Fatty acids with chain engths of up to 12 and 22 carbon atoms were quantiled by determining peak-area ratios with the 9:0 and L9:0 internal standards, respectively. In the GC analrses, an identical detector response was assumed for ill (saturated and unsaturated)
FAMEs.
Results
FFAs and TFAs in plasma of the nine MCAD, two MAD-m, and two VLCAD patients and 10 controls were determined. Fig. 1A shows a representative gas chro- Fig. lB . The presence of large peaks for 8:0 (no. 1), 10:0 (no. 3), and 10:1w6 (no. 4) is striking ( Fig. 2A) (4,6, 7) . In addition to 10:1w6, three small, unusual peaks (nos. 5, 7, and 9) were present. On the basis of retention time, elution sequence, and El mass spectra (Fig. 2, B-D) , these peaks were identified as 10:2w3, 12:1w7, and 14:1w9, respectively. Figure   1C shows the FFAMEs of symptomatic MAD-m patient 2 (sample 4, Table 1 ). The quite large peaks of 12:1w7 (no. 7) and especially 14:1w9 (no. 9) an striking.
As in the MCAD patient (Fig. 1B) 14:2w6 (no. 12) are preseni as unusual components (Fig. 1D) and 37.1 tmoIJL, respectively, with respective CVs of 3.7%, 5.5%, 11.9%, 14.3%, 4.7%, and 3.2%.
In Table 1 FFA and TFA concentrations in individual plasma samples of patients and controls under different metabolic conditions are shown. In all MCAD patients, FFA concentrations of 8:0, 10:1w6, and 10: 2w3 were increased.
The concentration of 8:0 was invariably greater than that of 10:0, and that of 10:1w6 was almost without exception between those of 8:0 and 10:0, findings that agree with data from Duran et al. (4) . From the similarities in FFA and TFA concentrations of 10:0, 10:1w6, and 10:2w3, we conclude that these fatty acids predominantly occur as FFAs. This has recently been established The MCAD FFA data are presented in Fig. 3A . The fatty acids 10:1w6 and 10:2w3 are pathognomonic for MCAD deficiency, and even asymptomatic patients can be recognized with these data. Additionally the concentrations of 8:0 can also be informative if other causes of increases, e.g., supplementation with medium-chain triglycerides, have been excluded. The MAf-m patients showed the whole spectrum of unusual fatty acids, pointing at disturbances of medium-and long-chain fatty acid oxidation. Again, FFA and TFA concentrations of 10:0, 10:1w6, and 10:2w3
and also of 12:1w7 and 8:0 are quite the same. Apparently, all these fatty acids are present almost exclu- (Fig. 3B) . The asymptomatic MAD-rn patient 1 (sample 1472 CLINICALCHEMISTRY, Vol. 41, No. 10, 1995 A 1), however, cannot be differentiated from a VLCAD patient on the basis of these data alone (Table 1) .
VLCAD patients can be differentiated from controls and from patients with other fatty acid oxidation disorders, especially on the basis of highly increased total 14:1w9 concentrations (Fig. 3C ) combined with normal 10:1w6 concentrations.
As in the MAD-rn patients, 14:1w9, 14:2w6, and 16:2w6 are largely present in the esterified form (Table 1) .
Discussion
To our knowledge, the unusual fatty acids 10:2w3, 12:1w7, 14:1w9, 14:2w6, and 16:2w6 have not been previously reported to be present in plasma of patients with a fatty acid oxidation disorder. Identification of these compounds has mainly been based on the combination of (relative) retention times and El mass spectra (Fig. 2) . All mass spectra show low-intensity molecular ions and mostly abundant M However, because of the lack of authentic reference compounds, the proposed structures are not absolutely definitive. In Fig. 4 possible routes of formation of these unusual fatty acids from (poly)unsaturated fatty acids are presented.
Linoleic acid 18:2w6 is /3-oxidized to 16:2w6 and subsequently to 14:2w6 (Fig. 4A ). Both intermediates can be found in plasma when VLCAD is deficient. As a 5-enoyl-CoA, 14:2w6, can be further /3-oxidized either by the conventional NADPH-independent pathway (16) to 12:2w6, or by an NADPH-dependent pathway (17-19) to 12: 1w6, both routes ultimately resulting in the formation of 10:1w6, a substrate for MCAD. Omega-6 polyunsaturated fatty acids such as 20:4w6 are probably also metabolized to 14:2w6 and then follow the metabolism of 18:2w6 as indicated in Fig. 4A . Figure 4B shows the formation of 14: 1w9 from oleic acid after two successive (3-oxidation cycles. This fatty acid accumulates in VLCAD deficiency and therefore is probably a substrate for VLCAD. In human beings the /3-oxidation pathways of (poly)unsaturated fatty acids are still partly unsolved. Tserng and Jin (17) found that, in the metabolism of oleic acid in rats, 14:1w9 is exclusively reduced to 14:0 and thus is not expected to accumulate in VLCAD deficiency. However, our findings of increased 14:1w9 in these patients suggest that in humans the reduction of 14:1w9 to 14:0 is of less importance than is the conversion by an acyl-CoA dehydrogenase.
Fatty acid 12:1w7 may be formed analogously from I palmitoleic acid (Fig. 4C ). This compound, being found both in MCAD and VLCAD deficiency, seems to be a substrate for both enzymes. 14:2 w6 Figure 4D shows a probable route of formation of 10:2w3. Linolenic acid 18:3w3 is (3-oxidized to 14:3w3, which can be metabolized further either by NADPHindependent or -dependent routes as shown in Fig. 4A boxylic acid, probably formed from 14:1w9 by w-oxidation. Apparently, long-chain dicarboxylic acids in plasma can also be determined with our method.
14:1 w9
The study of intermediates of fatty acid oxidation in plasma of patients with fatty acid oxidation disorders screening method for these disorders, the FFA determination is recommended because of its greater sensitivity, although the TFA determination is more specific with respect to MAD-rn and VLCAD deficiencies.
